{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:37:03Z","timestamp":1789522623033,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jphs.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T03:15:30Z","timestamp":1664334930000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells"],"prefix":"10.1016","volume":"150","author":[{"given":"Mana","family":"Azumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5898-7950","authenticated-orcid":false,"given":"Mikihiro","family":"Yoshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Nakachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Tsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jphs.2022.09.006_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13691-018-0350-1","article-title":"Uterine leiomyosarcoma well-controlled with eribulin mesylate","volume":"8","author":"Fujimoto","year":"2019","journal-title":"Int Cancer Conf J"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.006_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.52586\/S559","article-title":"Multifarious targets beyond microtubules-role of eribulin in cancer therapy","volume":"13","author":"Seshadri","year":"2021","journal-title":"Front Biosci (Schol Ed)."},{"issue":"10","key":"10.1016\/j.jphs.2022.09.006_bib3","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.006_bib4","first-page":"1013","article-title":"In\u00a0vitro and in\u00a0vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jphs.2022.09.006_bib5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/jjco\/hyz096","article-title":"Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes","volume":"49","author":"Kobayashi","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jphs.2022.09.006_bib6","doi-asserted-by":"crossref","first-page":"26000","DOI":"10.18632\/oncotarget.11006","article-title":"Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma","volume":"8","author":"Yurong","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jphs.2022.09.006_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3109\/07357900009012204","article-title":"The phosphoprotein Op18\/stathmin is differentially expressed in ovarian cancer","volume":"18","author":"Price","year":"2000","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.006_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3892\/ijo.2017.4085","article-title":"Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients","volume":"51","author":"Obayashi","year":"2017","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.jphs.2022.09.006_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/1541-7786.MCR-17-0230","article-title":"miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progression","volume":"16","author":"Chakravarthi","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jphs.2022.09.006_bib10","article-title":"STMN1 and MKI67 are upregulated in uterine leiomyosarcoma and are potential biomarkers for its diagnosis","volume":"26","author":"Hu","year":"2020","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.006_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1083\/jcb.140.1.131","article-title":"Regulation of microtubule dynamics by extracellular signals: cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells","volume":"140","author":"Gradin","year":"1998","journal-title":"J\u00a0Cell Biol"},{"issue":"Pt 1","key":"10.1016\/j.jphs.2022.09.006_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj3340023","article-title":"Role for protein phosphatases in the cell-cycle-regulated phosphorylation of stathmin","volume":"334","author":"Mistry","year":"1998","journal-title":"Biochem J"},{"issue":"33","key":"10.1016\/j.jphs.2022.09.006_bib13","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1021\/bi900776u","article-title":"Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation","volume":"48","author":"Alday","year":"2009","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.jphs.2022.09.006_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.786","article-title":"Stathmin dynamics modulate the activity of eribulin in breast cancer cells","volume":"9","author":"Yoshie","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"9","key":"10.1016\/j.jphs.2022.09.006_bib15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1093\/humrep\/deq190","article-title":"Possible role of the exchange protein directly activated by cyclic AMP (Epac) in the cyclic AMP-dependent functional differentiation and syncytialization of human placental BeWo cells","volume":"25","author":"Yoshie","year":"2010","journal-title":"Hum Reprod"},{"issue":"7","key":"10.1016\/j.jphs.2022.09.006_bib16","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1016\/S0021-9258(19)84915-3","article-title":"Intracellular substrates for extracellular signaling. Characterization of a ubiquitous, neuron-enriched phosphoprotein (stathmin)","volume":"264","author":"Sobel","year":"1989","journal-title":"J\u00a0Biol Chem"},{"issue":"18","key":"10.1016\/j.jphs.2022.09.006_bib17","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1093\/emboj\/16.18.5537","article-title":"Distinct roles of PP1 and PP2A-like phosphatases in control of microtubule dynamics during mitosis","volume":"16","author":"Tournebize","year":"1997","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.jphs.2022.09.006_bib18","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2013-03-492181","article-title":"Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies","volume":"122","author":"Oaks","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2022.09.006_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lfs.2018.08.063","article-title":"Protein phosphatase 2A as therapeutic targets in various disease models","volume":"210","author":"Baskaran","year":"2018","journal-title":"Life Sci"},{"issue":"19","key":"10.1016\/j.jphs.2022.09.006_bib20","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","article-title":"The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A","volume":"271","author":"Li","year":"1996","journal-title":"J\u00a0Biol Chem"},{"issue":"20","key":"10.1016\/j.jphs.2022.09.006_bib21","doi-asserted-by":"crossref","first-page":"14382","DOI":"10.1074\/jbc.274.20.14382","article-title":"A\u00a0protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A","volume":"274","author":"Ogris","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.006_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human malignancies","volume":"130","author":"Junttila","year":"2007","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.006_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-012-0993-z","article-title":"Expression of \u03b2-tubulin isotypes in urothelial carcinoma of the bladder","volume":"32","author":"Choi","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.jphs.2022.09.006_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrep.2020.100727","article-title":"Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein","volume":"21","author":"Nabekura","year":"2020","journal-title":"Biochemistry and Biophysics Reports"},{"issue":"4","key":"10.1016\/j.jphs.2022.09.006_bib25","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3892\/or.2017.5469","article-title":"Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18\/stathmin","volume":"37","author":"Shen","year":"2017","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.006_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13402-013-0163-3","article-title":"A\u00a0combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells","volume":"37","author":"Wu","year":"2014","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.006_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2011.05.021","article-title":"Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas","volume":"123","author":"Karst","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"18","key":"10.1016\/j.jphs.2022.09.006_bib28","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1073\/pnas.0702507104","article-title":"Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity","volume":"104","author":"Saal","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"43","key":"10.1016\/j.jphs.2022.09.006_bib29","doi-asserted-by":"crossref","first-page":"43ra55","DOI":"10.1126\/scitranslmed.3001065","article-title":"Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors","volume":"2","author":"Andersen","year":"2010","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.jphs.2022.09.006_bib30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1560","article-title":"The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas","volume":"13","author":"Hernando","year":"2007","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jphs.2022.09.006_bib31","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-12-0436","article-title":"Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma","volume":"18","author":"Brewer Savannah","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jphs.2022.09.006_bib32","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/cncr.26448","article-title":"The Akt\/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas","volume":"118","author":"Setsu","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.006_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2011.03.001","article-title":"Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition","volume":"122","author":"Wong","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jphs.2022.09.006_bib34","article-title":"Class III \u03b2-tubulin overexpression induces chemoresistance to eribulin in a leiomyosarcoma cell line","volume":"2018","author":"Yahiro","year":"2018","journal-title":"Anal Cell Pathol (Amst)."},{"issue":"8","key":"10.1016\/j.jphs.2022.09.006_bib35","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.21873\/anticanres.13559","article-title":"The effects of eribulin on breast cancer microenvironment identified using eribulin-resistant breast cancer cell lines","volume":"39","author":"Goto","year":"2019","journal-title":"Anticancer Res"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:02:43Z","timestamp":1761163363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861322000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1347861322000731"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2022.09.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}